NBTX
NASDAQ HealthcareNanobiotix S.A. - ADSs
Biotechnology
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
๐ Market Data
| Price | $37.53 |
|---|---|
| Volume | 144,468 |
| Market Cap | 1.91B |
| Beta | 0.560 |
| RSI (14-Day) | 57.8 |
| 200-Day MA | $28.91 |
| 50-Day MA | $39.88 |
| 52-Week High | $57.14 |
| 52-Week Low | $4.93 |
| Forward P/E | 485.82 |
| Price / Book | -18.85 |
๐ฏ Investment Strategy Scores
NBTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (55/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (21/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NBTX in your text
Paste any article, transcript, or post โ the tool will extract NBTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.